Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982.
about
One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonatesOne dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonatesOnce a day vs multiple doses a day regimen of gentamicin for treatment of suspected or proven sepsis in neonatesTobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic FibrosisPharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infectionProtective effect of piperacillin against nephrotoxicity of cephaloridine and gentamicin in animalsCumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosisValidation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapyAntibiotic treatment enhances the genome-wide mutation rate of target cellsBumetanide hyperpolarizes madin-darby canine kidney cells and enhances cellular gentamicin uptake by elevating cytosolic Ca(2+) thus facilitating intermediate conductance Ca(2+)--activated potassium channels.Assessment of aminoglycoside-induced hearing impairment in hospitalized neonates by TEOAE.Uptake of fluorescent gentamicin by vertebrate sensory cells in vivo.Fever and associated changes in glomerular filtration rate erase anticipated diurnal variations in aminoglycoside pharmacokineticsPrevention of adverse events in hospitalized patients using an antimicrobial review program.Effectiveness and toxicity of gentamicin in an experimental model of pyelonephritis: effect of the time of administrationOccurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy.Gentamicin induced ototoxicity during treatment of enterococcal endocarditis: resolution with substitution by netilmicin.Development of antibiotic treatment algorithms based on local ecology and respiratory surveillance cultures to restrict the use of broad-spectrum antimicrobial drugs in the treatment of hospital-acquired pneumonia in the intensive care unit: a retroRenal transport of antibiotics and nephrotoxicity: a review.Biosynthesis of 2-deoxystreptamine-containing aminoglycoside antibiotics.Community health workers can identify and manage possible infections in neonates and young infants: MINI--a model from Nepal.Importance of the aminoglycoside dosing regimen in the penicillin-netilmicin combination for treatment of Enterococcus faecalis-induced experimental endocarditisRole of aminoglycoside antibiotics in the treatment of intra-abdominal infection.Ceftazidime versus tobramycin-ticarcillin in the treatment of pneumonia and bacteremiaThe pharmacokinetics of once-daily dosing with gentamicin in women with postpartum endometritis.Renal disposition of gentamicin, dibekacin, tobramycin, netilmicin, and amikacin in humans.An update on otolaryngology in critical care.Prevention of hepatorenal toxicity with Sonchus asper in gentamicin treated rats.Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram-negative pyelonephritis in children.Induction and inhibition of pinocytosis by aminoglycoside antibioticsStudying outcomes of intensive care unit survivors: the role of the cohort study.Empirical antibiotic therapy for pneumonia in intensive care units: a multicentre, retrospective analysis of potentially pathogenic microorganisms identified by endotracheal aspirates cultures.Providing guidelines and education is not enough: an audit of gentamicin use at The Royal Melbourne Hospital.d-Methionine reduces tobramycin-induced ototoxicity without antimicrobial interference in animal models.Vestibulo-ocular reflex (VOR) in guinea pigs. Impairment induced by aminoglycoside antibiotics.Single daily amikacin versus cefotaxime in the short-course treatment of spontaneous bacterial peritonitis in cirrhotics.Molecular parameters involved in aminoglycoside nephrotoxicity.Drug-induced renal toxicity. Help in recognizing offending agents.Aminoglycoside-induced vestibular injury: maintaining a sense of balance.Extended-interval dosing of gentamicin for treatment of neonatal sepsis in developed and developing countries.
P2860
Q24235032-DE1FF807-156C-4CEE-9183-61EB020D2E78Q24244642-118579C4-9A53-4950-BFF4-16848FF02BA1Q24245588-910EEADF-1FFF-43DC-BB36-F25A3FCD8BF3Q26829604-F4975940-DB41-4B00-AC06-4B5ABBC008B5Q28328534-C7839358-A557-4585-A30B-D4125BDE7CB3Q28361543-F1681871-1B50-473B-BFC9-EC02710295ABQ28361867-1D69BF10-13A5-44EF-BD74-C307A1E92191Q28379292-1FE9ADF5-2191-42D2-AB9F-E742F3341E04Q28386555-E9BCEF7B-6884-4371-B215-07E718850A54Q30440719-75A8408E-16B4-4EC5-96B7-1E942A8C7DBEQ30461520-6EBCD973-08C2-441B-848E-24090957B417Q30494217-58FBFA0F-C263-4F8D-8356-2755C79E3FC1Q33751758-351B86FC-C9C3-4492-86BA-5CB385BBA42DQ33772759-30A34387-B597-421D-9F94-28B8B9103749Q33976169-9EA6D9B0-DA97-4280-9843-BD8B2375AAD8Q33982886-5B3E180D-4115-4794-B2CE-CFE12AF8A4BAQ34411596-571A287B-FF07-45DD-AEDF-505A0788E70FQ34468680-D131E7D3-57C2-4573-A5E9-3F35B5471495Q34472677-217E483B-57AB-431B-A530-8699C50DA38AQ34583543-859C1C12-C1AF-4645-B4CC-F77C3F6C1E25Q35090305-053AE946-BA58-4186-90A9-0B9ACE8A34C4Q35285645-B909ED49-E8A8-47BE-B9EC-9E075161EA12Q35538285-7DEE681B-34F7-4B13-8661-50BB3242A1CBQ35571259-CBD89227-1DC9-4874-9BC8-D81E4761DEC3Q35615484-32A0C8CB-0E46-4A70-8E42-948FC600BB5FQ35642347-6C319A04-0DA7-4F1D-B0B8-536CC268556BQ35746986-A170D391-4463-4669-8511-E8BB6D36D5B5Q35834985-BDC81EF7-5B79-4A1E-B07A-D0BAAF2386CBQ35885240-9AB4A861-6A88-43A8-A73D-95B183E04E31Q36004047-0435CCF8-D0D1-4F75-8640-DB379F4574E5Q36134894-AD2791B4-D1AE-4178-BD85-A9FA46A4F47DQ36167408-B1AE9505-D668-43A7-A4E1-6660290B42FEQ36366980-B8EE7812-2934-4A08-BC3F-449FDD1F45CAQ36446781-9D35A8A9-B2F2-465C-B782-66F08E3FDBBEQ36459939-7C945AC7-51A2-4363-A2F7-77F359DE5D97Q36496656-D0E7A44D-F6B3-4642-A358-B96CDD066A49Q36720602-D0B1494A-903A-4E3D-AF9A-CF4B1EF8D879Q37213753-15AC422B-4A11-4D77-A583-24654DD0F62AQ37224123-01B74CED-D751-4F85-84DD-02C9B65DF866Q37237625-B6E743AA-32F2-466F-997B-FC094AC8AF79
P2860
Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982.
description
1984 nî lūn-bûn
@nan
1984 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1984 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1984年の論文
@ja
1984年学术文章
@wuu
1984年学术文章
@zh-cn
1984年学术文章
@zh-hans
1984年学术文章
@zh-my
1984年学术文章
@zh-sg
1984年學術文章
@yue
name
Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982.
@ast
Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982.
@en
Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982.
@nl
type
label
Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982.
@ast
Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982.
@en
Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982.
@nl
prefLabel
Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982.
@ast
Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982.
@en
Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982.
@nl
P356
P1476
Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982.
@en
P2093
Dahlager JI
Kahlmeter G
P356
10.1093/JAC/13.SUPPL_A.9
P407
P478
13 Suppl A
P577
1984-01-01T00:00:00Z